Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world

doi:10.3389/fonc.2022.954203

科研成果详情

题名	Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world
作者	Feng, Jin-Kai 1; Liu, Zong-Han 1; Fu, Zhi-Gang 2; Chai, Zong-Tao 1; Sun, Ju-Xian 1; Wang, Kang 1; Cheng, Yu-Qiang 1; Zhu, Hong-Fei 1; Xiang, Yan-Jun1,3; Zhou, Li-Ping 1; Shi, Jie 1; Guo, Wei-Xing 1; Zhai, Jian 2; Cheng, Shu-Qun 1
发表日期	2022-11-25
发表期刊	FRONTIERS IN ONCOLOGY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	hepatocellular carcinoma (HCC) portal vein tumor thrombus (PVTT) transarterial chemoembolization (TACE) anti-angiogenic targeted therapy PD-1 inhibitor immune checkpoint inhibitor (ICI) combination therapy
摘要	PurposeThis study aimed to assess the efficacy and safety of a triple therapy that comprises transarterial chemoembolization (TACE), antiangiogenic-targeted therapy, and programmed death-1 (PD-1) inhibitors in a real-world cohort of patients with unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). MethodsConsecutive patients treated with TACE combined with antiangiogenic therapy and PD-1 inhibitors at the Eastern Hepatobiliary Surgery Hospital between June 2019 and May 2021 were enrolled. The baseline characteristics and treatment course of the patients were recorded. The tumor response was evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and HCC-specific modified RECIST (mRECIST). The overall survival (OS) and progression-free survival (PFS) of the patients were analyzed using the Kaplan-Meier method. Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. ResultsAs of the data cutoff on 30 August 2021, the median follow-up time was 10.0 (3.9-28.4) months. A total of 39 eligible patients were included. The objective response rate (ORR) and the disease control rate (DCR) were 35.9% and 74.4% according to the RECIST 1.1, and 48.7% and 84.6% according to mRECIST criteria, respectively. The median OS and PFS were 14.0 and 9.2 months, respectively. Moreover, 34 (87.2%) patients experienced at least one treatment-related AE and 8 (20.5%) patients experienced grade 3/4 treatment-related AEs. The most common treatment- and laboratory-related AEs were hypertension (46.2%) and decreased albumin (53.8%), respectively. No treatment-related mortality occurred during the study period. ConclusionsTACE combined with antiangiogenic-targeted therapy and immune checkpoint inhibitors may have promising anticancer activity in unresectable HCC patients with PVTT. AEs were manageable, with no unexpected overlapping toxicities.
资助项目	Clinical Research Plan of Shanghai Hospital Development Center [SHDC2020CR1004A]; Key Project of the National Natural Science Foundation of China [81730097]; National Natural Science Foundation of China [82072618]; National Key Research and Development Program of China [2022YFC2503700, 2022YFC2503701, 2022YFC2503703, 2022YFC2503705]
出版者	FRONTIERS MEDIA SA
出版地	LAUSANNE
ISSN	2234-943X
卷号	12 页码:954203
DOI	10.3389/fonc.2022.954203
页数	13
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:000894800000001
收录类别	SCIE ; SCOPUS ; PUBMED
URL	查看原文
PubMed ID	36505818
SCOPUSEID	2-s2.0-85143803513
通讯作者地址	[Cheng, Shu-Qun]Department of Hepatic Surgery VI,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University,Shanghai,China ; [Zhai, Jian]Department II of Interventional Radiology,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University,Shanghai,China
Scopus学科分类	Oncology;Cancer Research
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/172154
专题	第一临床医学院（信息与工程学院）、附属第一医院附属第一医院
通讯作者	Zhai, Jian; Cheng, Shu-Qun
作者单位	1.Department of Hepatic Surgery VI,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University,Shanghai,China; 2.Department II of Interventional Radiology,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University,Shanghai,China; 3.Department of Hepatobiliary Surgery,The First Affiliated Hospital,Wenzhou Medical University,Zhejiang,China
推荐引用方式 GB/T 7714	Feng, Jin-Kai,Liu, Zong-Han,Fu, Zhi-Gang,et al. Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world[J]. FRONTIERS IN ONCOLOGY,2022,12:954203.
APA	Feng, Jin-Kai., Liu, Zong-Han., Fu, Zhi-Gang., Chai, Zong-Tao., Sun, Ju-Xian., ... & Cheng, Shu-Qun. (2022). Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world. FRONTIERS IN ONCOLOGY, 12, 954203.
MLA	Feng, Jin-Kai,et al."Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world".FRONTIERS IN ONCOLOGY 12(2022):954203.